annual Report 2009 - STRATEC Biomedical AG

Consolidated Statement of Comprehensive Income
for the period from January 1 to December 31, 2009
of STRATEC Biomedical Systems AG
Note
2009
in v
2008
in v thousand
Sales (20) 79,589,273.42 60,971
Increase in volume of finished and unfinished products
and unfinished services (21) 7,013,579.47 6,219
Other own work capitalized (2) 625,493.50 456
Overall performance 87,228,346.39 67,646
Other operating income (22) 747,086.21 1,146
Cost of materials
a) Cost of raw materials and supplies 41,577,725.99 31,217
b) Cost of purchased services 1,426,656.33 946
43,004,382.32 32,163
Personnel expenses (23)
a) Wages and salaries 18,120,103.18 14,526
b) Social security contributions, pension
expenses and other benefits 2,591,466.37 2,168
20,711,569.55 16,694
Amortization of intangible assets and depreciation
(24) 2,573,305.89 2,285
of property, plant and equipment
Other operating expenses (25) 6,967,291.44 6,425
Income from profit transfer agreements -75,054.66 -71
Financial income 119,687.62 644
Financial expenses 214,245.34 224
Other financial income/expenses 549,483.12 -2,187
Net financial expenses (26) 379,870.74 -1,838
Operating result (EBT) 15,098,754.14 9,387
Taxes on income (15)
a) Current tax expenses 3,753,929.40 3,554
b) Deferred tax expenses -328,762.07 -298
3,425,167.33 3,256
Consolidated net income 11,673,586.81 6,131
Income and expenses recognized directly in equity (after taxes)
Currency translation of foreign financial statements 231,828.24 -391
Measurement of available-for-sale financial assets
as of balance sheet date 0.00 -105
Comprehensive income 11,905,415.05 5,635
Earnings per share in v (27) 1.03 0.54
Number of shares used as basis 11,346,814 11,359,898
Diluted earnings per share in v (27) 1.02 0.54
Number of shares used as basis (diluted) 11,425,923 11,387,716
48 stratec Annual Report 2009